RT期刊文章SR电子T1 Tenecteplase安全性和有效性和溶栓串联病变患者中风:EXTEND-IA秋明石油公司的因果分析试验摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯10.1212 SP / WNL。半岛投注体育官网0000000000207138 10.1212 / WNL。A1 0000000000207138 A1 Yogendrakumar, Vignan A1 Churilov,列昂尼德•米切尔,彼得·J A1 Kleinig Timothy J A1 Yassi Nawaf A1 Thijs,文森特A1吴,泰迪A1 Shah沾光A1贝利,彼得A1杜威,海伦米崔A1爱丽丝A1韦杰,菲利普•马MC A1 Tissa A1 Garcia-Esperon,卡洛斯A1云,杰弗里•A1钱德拉Ronil诉A1 Cordato,丹尼斯·约翰A1燕DMedSc伯纳德A1沙玛,选手Gagan A1德斯蒙德,帕特里夏·M A1帕森斯,杰弗里·艾伦·戴维斯A1马克·W A1唐南Stephen M A1坎贝尔,布鲁斯·c . v .年2023 UL //www.ebmtp.com/content/early/2023/03/06/WNL.0000000000207138.abstract AB背景和目的:的安全性和有效性tenecteplase串联病变患者中风是未知的。半岛投注体育官网我们进行了比较分析tenecteplase和串联病变患者溶栓。方法:我们首先比较tenecteplase的治疗效果和患者的溶栓串联使用个别患者病变EXTEND-IA秋明石油公司的数据试验。我们在初始评估颅内再灌注血管造影评估和90天的夫人序数物流和弗斯回归模型。因为两个关键结果,死亡率和症状性颅内出血,很少在收到那些溶栓EXTEND-IA秋明石油公司试验,我们生成的混合估计这些结果通过补充试验数据估计入射通过荟萃分析研究确定在系统回顾。然后计算未经调整的风险差异比较集中发病率估计对于那些接受溶栓试验中观察到的那些接收tenecteplase。结果:483名患者(15%)的七十一年EXTEND-IA秋明石油公司试验具有串联病变。病变患者,观察颅内再灌注在11/56(20%)的tenecteplase治疗患者与1/15(7%)患者溶栓治疗(优势比:2.19;95%置信区间:0.28—-17.29)。观察无显著差异在90天的夫人(常见或调整:1.48; 95% CI: 0.44-5.00). A pooled study-level proportion of alteplase associated mortality and symptomatic intracranial hemorrhage was 0.14 (95% CI: 0.08-0.21) and 0.09 (95% CI: 0.04-0.16), respectively. Compared to a mortality rate of 0.09 (95% CI: 0.03-0.20) and a symptomatic intracranial hemorrhage rate of 0.07 (95% CI: 0.02-0.17) in tenecteplase treated patients, no significant difference was observed.Conclusions: Functional outcomes, mortality, and symptomatic intracranial hemorrhage did not significantly differ between tenecteplase and alteplase treated tandem lesion patients.Classification of Evidence: This study provides Class III evidence that tenecteplase is associated with similar rates of intracranial reperfusion, functional outcome, mortality, and symptomatic intracranial hemorrhage compared with alteplase, in patients with acute stroke due to tandem lesions. However, the confidence intervals do not rule out clinically important differences.

map